California-based Dexcom (DXCM) is a global medical device company that makes glucose monitoring systems for people with diabetes. It recently introduced a new product named Dexcom ONE to expand access ...

Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...

DexCom posted another quarter of robust top-line growth that leaves the firm on track to meet our full-year expectations, and we’re standing behind our $315 fair value estimate. Importantly, DexCom’s ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom ...

DexCom’s U.S. revenue grew 15% to $841 million, while international revenue increased 16% to $316.1 million. The company’s sensor and other revenue, which represents 97% of total revenue, jumped 18% ...

The new partnership between DexCom and Google to build out a new class of continuous glucose monitors spells out an interesting future for Type 2 diabetes care – and market dynamics in that space. To ...

We recently published 10 Stocks Bleeding Early. DexCom, Inc. (NASDAQ:DXCM) is one of the worst-performing stocks on Monday. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to ...

DexCom's Q2 results came in a little short of Wall Street expectations. The company also narrowed its full-year revenue guidance, lowering the top end of the range. DexCom's U.S. launch of its G7 ...

Dexcom posted full-year performance that matched up closely with our estimates, and we’re leaving our fair value estimate unchanged. Reported 2021 revenue growth of 27% hit our projection on the nose.